Connect Biopharma (CNTB) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Connect Biopharma (CNTB) over the past year, losing 23.5% versus a loss of 46.9%. Xilio Therapeutics is the larger company by market cap ($59.3 million vs $55.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | XLO |
|---|---|---|
| Share price | $0.8807 | $9.01 |
| Market cap | $55.46M | $59.29M |
| 1-day change | -6.77% | 0.00% |
| YTD return | -66.50% | +0.56% |
| 1-year return | -46.93% | -23.48% |
| 5-year return | -94.50% | — |
| EPS (TTM) | $-1.19 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $12.59 |
| 52-week low | $0.85 | $6.47 |
| Distance from 52-week high | -76.95% | -28.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +567.65% | +121.98% |
| Average volume | 3.83M | 19.05K |
| Shares outstanding | 62.97M | 6.58M |
| Employees | 64 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed CNTB by 23.5 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Healthcare · Biotechnology · 64 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Healthcare · Biotechnology · 76 employees
CNTB vs XLO FAQ
Which is bigger, Connect Biopharma or Xilio Therapeutics?
Xilio Therapeutics (XLO) is larger, with a market capitalization of $59.29M compared with $55.46M for Connect Biopharma (CNTB).
Which stock has performed better over the past year, CNTB or XLO?
XLO returned -23.48% over the past 12 months, compared with -46.93% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.